Related Experiment Video
Updated: Feb 1, 2026

A Simple Flow Cytometric Method to Measure Glucose Uptake and Glucose Transporter Expression for Monocyte Subpopulations in Whole Blood
Published on: August 12, 2016
Influence of glucose transporter 1 activity inhibition on neuroblastoma in vitro
Yan Peng1, Si-Ning Xing1, Hu-Ying Tang1
1Department of Physiology, Chongqing Medical University, Chongqing 400016, China; Department of Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing 400016, China.
Abstract:
Most cancer cells predominantly produce their energy through a high rate of glycolysis in the presence of abundant oxygen. Glycolysis has become a target of anticancer strategies. Previous researches showed that glucose transporter 1 (GLUT1) inhibitor is effective as anticancer agents. This study assessed the effects of the selective GLUT1 inhibitor WZB117 on regulation of neuroblastoma (NB) cell line SH-SY5Y viability, cell cycle and glycolysis in vitro. SH-SY5Y cells were grown and treated with WZB117 for up to 72 h and then subjected to cell viability, qRT-PCR, Western blot and flow cytometry analysis. Level of ATP and LDH was also analyzed. The result showed that WZB117 treatment reduced tumor cells viability, downregulated level of GLUT1 protein. Moreover, WZB117 treatment arrested tumor cells at the G0-G1 phase of the cell cycle, induced tumor cells to undergo necrosis instead of apoptosis. In addition, WZB117 treatment downregulated the levels of intracellular ATP, LDH and glycolytic enzymes. Thus, WZB117-induced GLUT1 inhibition suppressed tumor cell growth, induced cell cycle arrest and reduced glycolysis metabolites in NB cells in vitro. This study suggested that GLUT1 can be used as a potential therapeutic target for NB.
Insights
The GLUT1 inhibitor WZB117 effectively reduced neuroblastoma cell viability and growth by inhibiting glycolysis. This targeted approach arrested the cell cycle and induced necrosis, suggesting GLUT1 as a promising therapeutic target for neuroblastoma.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cancer cells exhibit high glycolysis for energy production, making glycolysis a key target for anticancer strategies.
- Glucose transporter 1 (GLUT1) inhibitors have shown efficacy as anticancer agents.
Purpose of the Study:
- To evaluate the effects of the selective GLUT1 inhibitor WZB117 on neuroblastoma (NB) cell line SH-SY5Y viability, cell cycle, and glycolysis in vitro.
- To investigate WZB117 as a potential therapeutic target for NB.
Main Methods:
- SH-SY5Y cells were treated with WZB117 and analyzed for cell viability, gene expression (qRT-PCR), protein levels (Western blot), and cell cycle progression (flow cytometry).
- ATP and lactate dehydrogenase (LDH) levels were also measured.
Main Results:
- WZB117 treatment significantly reduced SH-SY5Y cell viability and downregulated GLUT1 protein levels.
- The inhibitor induced cell cycle arrest at the G0-G1 phase and promoted necrosis over apoptosis.
- WZB117 decreased intracellular ATP, LDH, and glycolytic enzyme levels.
Conclusions:
- WZB117-induced GLUT1 inhibition effectively suppressed neuroblastoma cell growth, induced cell cycle arrest, and reduced glycolysis metabolites in vitro.
- GLUT1 inhibition presents a potential therapeutic strategy for neuroblastoma treatment.
Related Concept Videos
Secondary Active Transport
Secondary Active Transport
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Primary Active Transport
Primary Active Transport
Active Transport
Primary active transporters, like Na+, K+ and -ATPase, directly utilize ATP to move ions across the membrane. These transporters play significant roles in various physiological processes. For instance, Na+, K+ and -ATPase maintain...

